Composition of the von Willebrand factor storage organelle (Weibel- Palade body) isolated from cultured human umbilical vein endothelial cells by unknown
Composition of the von Willebrand Factor Storage Organelle 
(Weibel-Palade Body) Isolated from Cultured 
Human Umbilical Vein Endothelial Cells 
B. M. Ewenstein,* M. J. Warhol,* R. I. Handin,* and J. S. Pober~ 
Department of Pathology and *  Division of Hematology, Brigham and Women's Hospital, and the ~  Departments of Pathology and 
• Medicine, Harvard Medical School, Boston, Massachusetts 02115 
Abstract.  von Willebrand factor (VWF) is a large, 
adhesive glycoprotein that is biosynthesized and 
secreted by cultured endothelial cells (EC).  Although 
these cells constitutively release VWF, they also con- 
tain a storage pool of this protein that can be rapidly 
mobilized. In this study, a dense organelle fraction 
was isolated from cultured umbilical vein endothelial 
cells by ceturifugation on a  self-generated Percoll gra- 
dietu.  Stimulation of EC by 4-phorbol  12-myristate 
13-acetate  (PMA) resulted in the disappearance of this 
organelle fraction and the synchronous loss of Weibel- 
Palade bodies as judged by immunoelectron micros- 
copy. Electrophoretic and serologic analyses of biosyn- 
thetically labeled dense organelle fraction revealed that 
it is comprised almost exclusively of VWF and its 
cleaved pro sequence. These two polypeptides were 
similarly localized exclusively to Weibel-Palade bodies 
by ultrastructural  immunocytochemistry. The identity 
of the dense organelle as the Weibel-Palade body was 
further established by direct morphological examina- 
tion of the dense organelle fraction.  The VWF derived 
from this organelle is distributed among unusually 
high molecular weight multimers composed of fully 
processed monomeric subunits and is rapidly and 
quantitatively secreted in unmodified form after PMA 
stimulation.  These studies: (a) establish that the 
Weibel-Palade body is the endothelial-specific storage 
organdie for regulated VWF secretion; (b) demon- 
strate that in cultured EC, the VWF concentrated in 
secretory organdies is of unusually high molecular 
weight and that this material may be rapidly mobilized 
in unmodified form; (c) imply that proteolytic process- 
ing of VWF involved in regulated secretion takes place 
after translocation to the secretory organelle;  (d) pro- 
vide a basis for further studies of intracellular protein 
trafficking in EC. 
V 
oN Willebrand  factor (VWF)  ~ is a  large,  adhesive 
glycoprotein  synthesized  by vascular  endothelium 
(Jaffe et al.,  1973; Jaffe et al., 1974) and megakaryo- 
cytes  (Nachman  et  al.,  1977). In  plasma,  it  serves as  a 
stabilizing "carrier" protein for factor VIII with which it cir- 
culates as a complex (Weiss et al.,  1977). In blood vessels, 
VWF serves as a platelet-subendothelial  "molecular bridge" 
in the initiation  of the hemostatic  plug at the site of vessel 
wall damage (Stel et al., 1985; Turitto et al., 1985). Although 
the precise nature of this  bridging  remains to be defined, 
binding  to  both  vascular  subendothelium  as  well  as  to 
purified collagens and to platelet membrane glycoprotein Ib 
has been demonstrated in a number of studies  (Kao et al., 
1979; Meyer and Baumgartner,  1983; Houdijk et al.,  1985). 
In plasma, VWF circulates as a series of disulfide-linked bet- 
erogeneous multimers with apparent  molecular masses of 
A preliminary account of this work was presented at the December 1986 
meeting of the American Heart Association in Dallas, Texas. 
1.  Abbreviations  used  in  this paper:  EC,  endothelial  cells;  VWE  yon 
Willebrand factor. 
0.4-20  x  10  ~, assembled chiefly from Mr 220,000 subunits 
(Rugged and Zimmerman,  1980). A number of clinical ob- 
servations suggest that the hemostatic potency of VWF is at 
least partially proportional to multimer size (Zimmerman et 
al., 1983). The existence of a physiologically important  stor- 
age pool of VWF is suggested by the observations that several 
stimuli including exercise,  adrenalin  (Prentice et al.,  1972), 
and desmopressin acetate (Rugged et al.,  1982) rapidly in- 
crease plasma VWF levels and ameliorate clinical bleeding. 
Cultured endothelial  cells (EC)  secrete VWF in both a 
constitutive  (Jaffe et al.,  1973) and  regulated  manner.  A 
number of agents,  including  thrombin,  calcium ionophore 
A23187, and 4-phorbol  12-myristate  13-acetate (PMA) can 
induce the rapid release of preformed VWF (Loesberg et al., 
1983; de Groot et al.,  1984). This  regulated  secretion of 
VWF by EC, observed in vitro,  may be the mechanism by 
which VWF is rapidly mobilized in vivo.  Reinders  et al. 
(1984) reported the isolation of a VWF-containing  organelle 
from human umbilical vein endothelium that was not present 
in cells pretreated with PMA. This organdie was postulated 
to be identical to the Weibel-Palade body (Weibel and Palade, 
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elle previously shown by immunohistochemical techniques 
to contain VWF (Wagner et al., 1982; Hormia et al., 1984; 
Warhol and Sweet, 1984). This conclusion was inferred from 
the coincident disappearance of characteristic granular immu- 
nofluorescent staining for VWF thought specific for Weibel- 
Palade bodies.  However,  vascular endothelial cells from a 
number of sources, including bovine aorta and human adi- 
pose tissue capillaries, lack identifiable Weibel-Palade bod- 
ies yet show granular staining patterns (Schwartz, 1978; Kern 
et al., 1983). Therefore, the association of  the Weibel-Palade 
body with regulated secretion of VWF can only be rigor- 
ously established at the ultrastructural level. 
The primary structure of plasma VWF has been ascer- 
tained by classical protein sequencing techniques (Titani et 
al., 1986). Recently, several groups have reported the clon- 
ing of VWF cDNA from EC (Ginsburg et al., 1985; Lynch 
et al., 1985; Verweij et al., 1985; Sadler et al., 1985) and the 
complete sequence of the VWF transcript has been obtained 
(Bonthron et al., 1986). Comparison with the plasma protein 
sequence predicts that the primary VWF translational prod- 
uct contains an amino terminal ~re" or signal sequence and 
an  adjacent Mr  100,000 "pro" sequence,  identical with a 
plasma protein previously called VWF antigen II (Fay et al., 
1986). VWF antigen H is also biosynthesized  and released 
by cultured EC (McCarroll et al.,  1985). The predominant 
subunit size of VWF secreted by cultured EC is Mr 220,000. 
An  intracellular precursor  form of Mr  260,000  has  been 
identified  as the earliest biosynthetic intermediate in both hu- 
man and bovine EC  lysates (Wagner and Marder,  1983; 
Lynch et al., 1983). This molecular species is known to un- 
dergo a  series of posttranslational modifications including 
dimerization, interchain disulfide formation, carbohydrate 
processing, removal of the Mr  100,000 pro sequence,  and 
multimerization of the dimers. Incomplete cleavage of the 
propolypeptide leads to the release of small quantities of Mr 
275,000 subunits that are also incorporated into multimers 
(Wagner and Marder, 1983; Lynch et al., 1986). The intra- 
cellular localization of VWF processing has been inferred 
from pulse-chase experiments in the presence of metabolic 
inhibitors (Wagner and Marder, 1984). By these methods, it 
was shown that the cleavage of proVWF to its mature form 
occurs  in  the  Golgi and  "later compartments:  However, 
these experiments,  which analyzed unfractionated EC ly- 
sates, could not differentiate between processing of VWF 
destined for constitutive as opposed to regulated secretion. 
To ascertain the form of VWF involved in regulated secre- 
tion, we have isolated a biosynthetically labeled dense or- 
ganelle  from  cultured  human  umbilical  vein  endothelial 
cells. The isolated organelle was found to be ultrastructurally 
indistinguishable from Weibel-Palade bodies as previously 
described in intact ceils, lmmunochemical analysis of the 
protein contained in this cell fraction revealed that it is com- 
prised almost exclusively of VWF and the cleaved VWF pro 
sequence, and by ultrastructural immunocytochemistry,  both 
proteins were shown to colocalize in Weibel-Palade bodies. 
The VWF derived from this organdie is distributed among 
unusually high molecular weight multimers composed of 
fully processed monomeric forms. Furthermore, we demon- 
strate the rapid and quantitative release of both proteins into 
culture medium following PMA stimulation and the con- 
comitant loss of  Weibel-Palade bodies from the treated cells. 
Materials and Methods 
Cell Source and Culture 
Endothelial cells were isolated from 1-4 human umbilical vein segments by 
collagenase digestion as previously described (Gimbrone,  1976) and cul- 
tured  in Medium  199  (Biofluids,  Rockville,  MD) containing 20%  heat- 
inactivated FCS (Gibco, Grand Island, NY) supplemented with penicillin 
(125 U/mi), streptomycin (125 ~g/mi), and 2 mM L-glutamine. Cells were 
passaged under the conditions of Thornton ct al. (1983),  additionally sup- 
plementing  the  medium  with porcine  heparin  (100  gg/ml)  from  Sigma 
Chemical Co. (St. Louis, MO) and endothelial cell growth factor (50/~g/ml) 
from Meloy Laboratories,  Inc.  (Springfield, VA). The plastic substratum 
(either T75 flasks or 10-cm petri dishes, both from Coming Glass Works, 
Coming, NY) was coated with gelatin (Difco Laboratories, Inc., Detroit, 
MI) before plating. Cells in these experiments were passaged one to three 
times from primary cultures. For radiolabeled experiments, EC were main- 
tained for 3 d in the above medium supplemented with L-[35S]cysteine (0.5 
Ci/mi; 1,000 Ci/mmol) (New England Nuclear, Boston, MA), then chased 
for 3 h with unlabeled medium. Where indicated, confluent cultures were 
rinsed three times with Hanks' balanced salt solution (HBSS) (Gibco), then 
treated with  100 nM PMA (Sigma Chemical Co.) in fresh medium.  For 
analysis of radiolabeled proteins, the 3 d conditioned medium, the medium 
conditioned during PMA or mock-PMA treatments (releasates),  and the 
cell layer were separately collected. 
Subce[lular Fractionation 
Cells were harvested by treatment with trypsin-EDTA (Gibco) diluted I:I 
with HBSS minus calcium and magnesium (3 ml/plate) for 2 rain at 370C. 
The resultant cell suspension was transferred to tubes containing an equal 
volume of soybean trypsin inhibitor (I mg/rrd; Cooper BioMedical, Inc., 
Malvern, PA) in an isotonic buffer containing 20 mM Tris HCI (pH 7.2), 
0.2 M sucrose, and I raM EDTA. In general, 2-6 million cells were pelleted 
at 600 g for I0 min, resospended in I ml fresh buffer, and subjected to 25-30 
strokes in a ground-glass Dounce homogenizer (made by Kontes Glass Co., 
Vineland, NJ) at 4°C. Nuclei and cellular debris were removed by centrifu- 
gation at 600 g for 10 min. The resultant "preclcared" supernatant was fur- 
ther fractionated on Percoll. In experiments directed toward morphological 
characterization of isolated fractions, the number of endothelial cells was 
increased to 40-60 million. This larger number of cells appeared to dimin- 
ish the resolution of the gradient, but was necessary to obtain sufficient ma- 
terial for preparation of thin sections (see below). 
Perco11 gradient ccntrifugation was carried out in a SS24 rotor using a 
centrifuge (model RC-5B; Sorvall Instruments Division, DuPont Co., New- 
ton, or). A 10-ml Oakridge tube (Nalge Co., Div. of Sybron Corp., Roches- 
ter,  NY) was filled with 8.5 mi of a  suspension containing 50%  Percoll 
(Pharmacia, Uppsala, Sweden), 0.25 M sucrose, pH 7.2, and a 0.2 mi cush- 
ion of 2.5 M  sucrose was carefully undcrlayered.  The preclcared cell ho- 
mogenates (0.8 ml) were carefully layered on top then banded through a self- 
generated density gradient for 65 rain at 40,000 g. Fractions (0.8 mi) were 
manually collected from the top of the gradient. The average density of each 
fraction was determined by weighing. Radiolabeled proteins were extracted 
from gradient fractions by the addition of an equal volume of a buffer con- 
taining 2% NP-40, 25 mM NaC1, 25 mM Tris-HCl (pH 7.4), 4 mM EDTA, 
4 mM phenyimethyl sulfonyl fluoride, 2 mM N-ethylmaleimide, and 2 mM 
iodoacetic acid (all from Sigma Chemical Co.). 
Inhibition ELISA 
VWF antigen was quantitatively measured by an inhibition ELISA using an 
avidin-biotin-peroxidase detection system.  Microtiter plates were coated 
overnight at 4°C with 50 ng of highly purified human VWF, washed, and 
then  incubated  for 2  h  at  20°C  with  100  ttl  of affinity-purified rabbit 
anti-VWF antiserum that had been preincubated with known concentrations 
of purified VWF protein (standards) (Loscalzo and Handin, 1984) or VWF- 
containing media or cell lysate (unknowns). After incubation overnight at 
room temperature, plates were washed and treated sequentially with bio- 
tinylated second antibody (goat anti-rabbit IgG) and with avidin-biotin- 
peroxidase complex  (Vector Laboratories,  Inc.,  Burlingame,  CA).  After 
washing, the plates were treated with the chromogenic substrate o-phenyl- 
enediamine 0.5 mg/ml in 140 ttl of phosphate/citrate buffer (pH 5.0) contain- 
ing 0.025 % H202. Color development was stopped after 10-15 min by the 
addition of 40 ttl 2M H2SO4 and the A490 was determined on a Minireader 
II (Dynatech Laboratories, Inc., Alexandria, VA). VWF antigen concentra- 
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aliquots. 
Protein Electrophoresis 
SDS PAGE of reduced proteins was carded out on slab gels of either 5 % 
acrylamide or linear gradients of  4-13 % acrylamide using the buffer system 
of  Laemmli (1970); all reagents were from BioRad Laboratories (Richmond, 
CA). Fixed and stained gels were equilibrated with Autofluor (National Di- 
agnostic, Inc., Somerville, NJ) for 1 h before drying and autoradiography. 
Agarose slab gel electrophoresis was carded out on a water-cooled, hori- 
zontal electrophoresis cell (BioRad Laboratories). Gels consisting of 2% 
agarose (Standard Low mr from BioRad Laboratories), 0.1% SDS, 0.05 M 
phosphate buffer (pH 7.0) were run for 3.5 h at 100 V (electrode buffer 0.1 
M  phosphate buffer, pH  7.0  with 0.1%  SDS),  then fixed,  stained,  and 
equilibrated with Antofluor and dried before autoradiography. 
Immunoprecipitation 
Radiolabeled proteins were isolated by precipitation with 1-10 gl of mouse 
monoclonal  antibody  (4°C,  16  h)  followed by  Sepharose-bound rabbit 
anti-mouse Ig (20°C, 2 h) (Miles-Yeda Ltd. Rehovot, Israel). For quantita- 
tive  immunoprecipitation,  rabbit  anti-mouse  gamma  globulin  (Cappel 
Laboratories, Inc., Cochranville, PA), which was previously incubated with 
sepharose-bound protein A (Sigma Chemical Co.), was used in place of the 
aforementioned rabbit anti-mouse reagent. Precipitates were washed four 
times with 0.1 M Tris HCI pH 8.0, 0.5% NP-40, 0.5% deoxycholate, 0.1% 
SDS,  2  mM EDTA and 2  mM phenylmethylsulfonyl fluoride, and then 
eluted by boiling for 2  min in SDS PAGE sample buffer containing 1% 
2-mercaptoethanol. Anti-VWF antibody was purchased from Cappel Labo- 
ratories, Inc.; anti-fibronectin antibody (Anti-FN Human, type I) was pur- 
chased from Calbiochem (341646;  La Jolla,  CA).  Five separate murine 
monoclonal antibodies to the VWF pro sequence (anti-proVWF, Fay et al., 
1986) were kind gifts of Dr. E  Fay (University of Rochester, New York). 
Electron Microscopy 
Confluent 10-cm petri dishes of EC were treated for various times with 
100 nM PMA as described above, rinsed twice with 5 ml of HBSS, then 
rapidly fixed in situ with 3% paraformaldehyde, 0.1% glutaraldehyde (voi/ 
vol) for 10 min at 20°C. The cells were harvested by gentle scraping and 
pelleted for 10 s in an Eppendorf  centrifuge (model 5414; Brinkmann Instru- 
ments Co., Westbury,  NY). 
The pellets were embedded using a  Lowicryl K4M (Balzers, Hudson, 
NH) protocol (Roth, 1982). After thin sectioning, VWF and proVWF were 
identified by immunochemical staining with either rabbit anti-human VWF 
(Dako Corp.,  Santa Barbara,  CA) or mouse monoclonal antibody (anti- 
VWF and proVWF, as above), rabbit anti-mouse Ig (Dako Corp.), and 
staphylococcal protein A  (Sigma Chemical Co.) -colloidal gold as previ- 
ously described (Warhol and Sweet, 1984). The number of WeibeI-Palade 
bodies in various EC preparations was quantitated by visually counting the 
number in 300 separate sectioned cell profiles for each group by two differ- 
ent "blinded" observers. 
For electron microscopy of isolated Percoll gradient fractions, aliquots 
of these fractions were subjected to recentrifugation of 100,000 g for 1 h in 
an ultracentrifuge (model L5-50; Beckman Instruments, Inc., Pain Alto, 
CA). Biological material was carefully aspirated away from the packed Per- 
coll, fixed in 3% paraformaldehyde, 0.1% glutaraldehyde for 1 h at 20°C, 
and repelleted. To aid in microsectioning, the fixed organelles were over- 
layered with 10% gelatin before osmium postfixation. Samples were embed- 
ded in Poly/bed 812 (Polysciences, Inc., Warrington, PA), sectioned, then 
double stained with uranyl acetate and lead citrate. 
Results 
Effect of  PMA on VWF  Release and Endothelial 
Cell Ultrastructure 
PMA is thought to activate protein kinase C in a number of 
cell types (Nishizuka,  1984) and has been shown to rapidly 
increase the amount of  VWF released by cultured human en- 
dothelial cells (Loesberg et al., 1983; Reinders et al., 1985). 
To determine whether the action of this agent could be cor- 
Table I. Effects of  PMA on Endothelial Cell 
Weibel-Palade Body Content and VWF  Release 
Time 
0 man  15 rain  30 man 
Weibel-Palade bodies*  PMA  25  2  0 
VWF in culture mediums  PMA  0  1,301  2,158 
Mock  0  191  290 
Difference  0  1,110  1,868 
* Total  number of organdies seen in 100 cells. Average of two blinded ob- 
servers. Total  VWF (nanograms)  detected in conditioned culture medium of 
cells treated with 1130 nm PMA. A background  of 43 rig/flask was subtracted 
from each time point. 
Total VWF (nanograms)  detected in conditioned culture  medium of mock- 
treated cells. A background 0f55 ng/ttask was subtracted from each time point. 
related  with  the  Weibel-Palade  content  of  cultured  en- 
dothelium, confluent cells were treated for 0, 15, and 30 min 
with  100 nM PMA and fixed in situ.  Untreated cells con- 
tained numerous Weibel-Palade bodies that clearly stained 
with rabbit anti-human VWF visualized with colloidal gold 
whereas PMA-treated cells were largely devoid of such bod- 
ies. Quantitative analysis of multiple cells revealed a >90 % 
reduction in Weibel-Palade bodies at 15 min and a virtual ab- 
sence of these structures 30 min posttreatment (Table I). To 
correlate VWF release during this time period, aliquots of 
culture medium from PMA- and mock-treated cells were as- 
sayed for VWF by inhibition ELISA. The quantity of VWF 
released as a consequence of secretagogue stimulation was 
determined by subtracting the VWF released constitutively 
(by mock-treated cells)  from the  total  VWF  released by 
PMA-treated cells. A dramatic increase of  VWF release over 
constitutive levels was noted in stimulated cells during the 
first 30 min of treatment. In experiments carried out to 6 h 
(not shown),  the  subsequent  rate of continued release of 
VWF from PMA-treated cells was  seen to parallel that of 
mock-treated endothelial cell cultures. 
Interestingly, a number of cells examined after 15 min of 
PMA treatment showed events suggestive of membrane fu- 
sion and degranulation at the cell surface (Fig.  1 B). At 30 
min posttreatment, a small number of vacuolated structures 
could be discerned that labeled for VWF (Fig.  1 C).  The 
genesis of these structures and their relationship to Weibel- 
Palade bodies is unknown. 
PercoU Gradient 
When radiolabeled endothelial cells were subfractionated on 
a  self-generated Percoll gradient, the bulk of radioactivity 
was recovered in a cytosolic (p =  1.02) and in a buoyant (p 
=  1.05) organelle fraction (Fig. 2 A). The profile of radioac- 
tivity was found to closely parallel that of total protein as 
measured by a quantitative Coomassie Blue assay (Bradford, 
1976; data not shown). Pretreatment of the endothelial cells 
with PMA did not materially alter the profile of either radio- 
activity or total protein. Analysis by inhibition ELISA of  gra- 
dient fractions from untreated cells revealed the presence of 
two distinct peaks of VWF activity (Fig. 2 B).  The more 
buoyant fraction (p =  1.05) corresponded to the second peak 
of radioactivity while a denser, broad fraction (p  =  1.10), 
containing the bulk of intracellular VWF, was found in gra- 
dient fractions containing comparatively little radioactivity. 
Ewenstein et al.  Isolation and Composition of Weibel-Palade Bodies  1425 Figure 1. (A) Control endothelial  cell cultures labeled  with rabbit polyclonal anti-VWE  A representative  endothelial  cell contains three 
Weibel-Palade  bodies labeled  with the anti-VWF  (arrows). (B) An endothelial  cell  15 min after treatment with PMA. The number of 
Weibel-Palade  bodies seen  is markedly reduced (see Table I). One residual  body labeled  with  anti-VWF  seems to be in the process of 
being extruded from the cell (arrow). (C) An endothelial  cell 30 rain after treatment with PMA. No definite Weibel-Palade  bodies are 
identified.  Rare cells contain faintly electron dense granular material  labeled  with anti-VWF within cytoplasmic vacuoles.  Bar,  150 ran. 
4C 
3O 
% 
20 
500 
,~250 
'A 
// 
~3~.JC  e" 
C~-- 
B 
I  2  5  4  5  6  7  S  9  t0  11  t2 
Fracl/on Number 
1.20 
115 
IlO 
1.05 
1.00 
In contrast,  homogenates of cells pretreated with PMA ex- 
hibited a  nearly quantitative  loss of this denser VWF-con- 
taining peak. 
To better characterize these fractions, unlabeled endothe- 
lial cells were similarly  fractionated for morphological ex- 
amination. Electron microscopic analysis of the buoyant or- 
ganelle  fraction  (Fig.  3  A)  revealed  the  presence  of  a 
heterogeneous population of subcellular organdies includ- 
ing rough endoplasmic  reticulum,  plasma membrane,  and 
Figure 2.  Percoll  gradient  fractionation  of [35S]cysteine-labeled 
endothelial  cell homogenates.  (A) Cells were labeled  for 3 d then 
subjected  to a  30-min treatment with  100 nM PMA (o------e)  or 
mock  treatment  (o  o).  After  trypsinization,  treated  or  un- 
treated  cells  were homogenized and subjected  to Percoll  gradient 
centrifugation  (40,000 g; 65 min) as described in Materials  and 
Methods.  Fractions (0.8 ml) were manually collected  from the top 
of  the gradient and the total radioactivity in each fraction calculated 
from the amount of radioactivity in 10-gl aliquots.  (B) The total 
VWF content of  fractions 1-10  was determined by inhibition ELISA 
of 50-1d aliquots  of detergent-solubilized  fractions,  symbols as in 
A. Average density  (o -  -  o) was determined by the weighing  of 
aliquots. 
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micrographs of Percoll fractions 
of endothelial cell homogenates. 
(A) The buoyant organelle frac- 
tion  consists  of a  heterogenous 
population of organeUes. (B) The 
dense organelle fraction consists 
principally  of organelles of the 
size  and  lamellar  substructure 
typical of endothelial cell Weibel- 
Palade bodies. In this overloaded 
gradient, mitochondria  were found 
to be the predominant contami- 
nating organelle.  (C) The same 
field  as  B,  magnified ×2.  m, 
Mitochondria; w, Weibel-Palade 
body. Bar, 100 am. 
possibly Golgi apparatus.  In contrast,  the denser fraction 
(Fig. 3, B and C) was seen to consist largely of organelles 
that were morphologically indistinguishable from Weibel- 
Palade bodies seen in  intact untreated cells.  In this  over- 
loaded gradient, the principal contaminating organelles were 
mitochondria. 
Analysis by SDS PAGE (Fig. 4 A) of fractions 1-10 from 
untreated labeled endothelial cells revealed that the denser 
fraction consisted principally of two proteins of Mr 220,000 
and  100,000, respectively.  Both  proteins  were  selectively 
depleted from homogenates of pretreated ceils (Fig. 4 B). 
Longer exposures (up to 10 times that shown) failed to reveal 
the presence of any other protein that was similarly enriched 
in this fraction. 
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[3~S]cysteine-labeled endothelial homogenates. (A) Mock-treated 
(control) cells and (B) PMA-treated cells were analyzed on differ- 
ent sides of the same slab gel.  10-gl aliquots of Percoll gradient 
fractions (from Fig. 2 A) were subjected to SDS PAGE (4-13% 
acrylamide) and analyzed by autofluorography.  Initial fluorographs 
(lanes 1-10, le~) were obtained at 16 h. Longer exposures (5 d) of 
lanes 6-10 (right) were obtained to better visualize the contents 
of the  dense  organelle  fractions.  Numbers  on left  indicate Mr 
X  10  -3. 
Serological Identification of  the Principal 
Proteins of  the Dense OrganeUe 
To identify the principal protein constituents of the isolated 
Weibel-Palade bodies,  [35S]cysteine-labeled  dense-fraction 
extracts, PMA releasates, and 3-d conditioned medium were 
subjected  to  immunoprecipitation  using  either  anti-VWF 
(Fig. 5, lanes b-d) or anti-proVW (Fig. 5, lanes e-g) mono- 
clonal  antibodies.  VWF  isolated  from  all  three  sources 
showed an identical electrophoretic mobility with Mr 220000. 
Similarly,  anti-proVWF  antibodies  identified the  cleaved 
Mr  100,000 pro sequence in the dense fraction and in both 
media sources. Repetition of these experiments on several 
occasions failed to reveal the presence of  any uncleaved (i.e., 
Mr 275,000)  forms. Thus,  all of the immunoreactive mate- 
rial identified by the anti-proVWF appears to be in the form 
of cleaved pro sequence. Parallel precipitation with mono- 
clonal anti-fibronectin antibody (Fig. 5, lanes h-j) demon- 
strated the presence of  biosynthetically labeled fibronectin in 
3-d medium but not in the dense organelle fraction nor in 
PMA releasates. Furthermore, both VWF and the proVWF 
polypeptide could be quantitatively depleted from labeled 
dense-fraction extracts using monoclonal antibodies (Fig. 6), 
implying  that  each  band  represents  only  a  single  poly- 
peptide. 
Ultrastructural Localization  of VWF and 
Its Cleaved Pro Sequence 
Ultrastructural localization of VWF and its cleaved pro se- 
quence was carried out using Lowicryl fixation and indirect 
immunochemical staining with protein A-colloidal gold. Be- 
cause both polypeptides had been previously demonstrated 
in the dense organelle fraction isolated in the biosynthetic ex- 
perirnents, it was expected that the same proteins should be 
identifiable in Weibel-Palade bodies by immunoelectron mi- 
croscopy. Indeed, indistinguishable staining of every Wei- 
bel-Palade body was observed using monoclonal antibodies 
against VWF and proVWE respectively (Fig. 7, A and B). 
Comparison of  Dense OrganeUe  Proteins and 
PMA-induced  Releasates 
To characterize the  VWF  released  during  PMA  induced 
secretion, mock-induced and PMA-induced releasates were 
compared by coelectrophoresis with material obtained from 
dense  organelle  fractions derived from mock-treated and 
PMA-treated endothelial cells.  Under reducing conditions 
on SDS polyacrylamide gels (Fig. 8 A), the two previously 
identified bands corresponding to VWF and the cleaved pro 
sequence were observed both in the dense fraction of mock- 
treated cells and in the releasate from PMA-treated cells. In 
contrast, a much smaller quantity of VWF was noted in the 
releasate from untreated cells.  Under nonreducing condi- 
tions on 2% SDS agarose gels (Fig.  8 B), a series of large 
molecular weight forms of VWF was observed both in the 
dense fraction and in the PMA-induced releasate. The distri- 
bution of VWF multimers from either source was virtually 
identical and thus appears not to have been altered in the pro- 
cess of secretion. The multimers were of strikingly high mo- 
lecular weight compared with those seen in VWF isolated 
from 3-d conditioned medium (Fig. 8 B, lane e). In addition, 
a number of constitutively secreted proteins of lower molec- 
ular weight were seen in conditioned media from both PMA- 
treated and mock-treated cells. 
Discussion 
Human vascular endothelial cells in culture biosynthesize 
VWF and secrete this protein in both a constitutive and regu- 
lated manner.  We  have isolated  a  radiolabeled dense  or- 
ganelle fraction from cultured human EC and have shown 
that is the source of VWF released by treatment with PMA 
(Fig.  8). 
The Journal of Cell Biology, Volume  104, 1987  1428 Figure  5.  Serologic  identification of the  principal  proteins  of 
purified  [3sS]cysteine-labeled  Weibel-Palade  bodies.  The deter- 
gent-solubilized organelle (Fig. 2 A, fractions 7 and 8) was ana- 
lyzed by SDS PAGE (5% acrylamide; lane a) and compared with 
immunoprecipitates of VWF (lanes b-d), proVWF (lanes e, fand 
g) or fibronectin (lanes h-j) that were prepared from detergent ex- 
tracts of the dense organdie (lanes b, e, and h), from PMA relea- 
sates (c, f, and i), and from 3-d conditioned medium (lanes d, g, 
and j). All samples are from the same labeled cell preparation, but 
immunoprecipitates from each  fraction  were  subjected to  SDS 
PAGE on replicate slab gels. Numbers on left indicate M,  ×  10  -3. 
The data presented in this study demonstrate an identity 
between the dense organelles isolated by Percoll subcellular 
fractionation and Weibel-Palade bodies seen by immuno- 
electron  microscopy.  Specifically,  electron  microscopic 
analysis of the dense VWF-rich peak on Percoll gradients re- 
vealed a predominance of organelles morphologically indis- 
tinguishable from Weibel-Palade bodies. In addition, we ob- 
served a temporal relationship after PMA stimulation of the 
disappearance of Weibel-Palade bodies as judged by mor- 
phometric analysis, the loss of the dense VWF-rich peak on 
Percoll gradient, and the accumulation of VWF in culture 
medium. The established identity between the protein con- 
tent of the dense organelle fraction and the PMA-releasates 
of [3sS]cysteine-labeled cells strongly suggests that these or- 
ganelles are secretory in nature. This latter conclusion is in 
concordance with previous observations of Weibel-Palade 
bodies fusing with outer cell membranes in stimulated toad 
aorta (Fujimoto, 1982) and extra-alveolar vessels from lungs 
of rabbits (McNiffand Gil, 1983). Our ultrastructural results 
confirm previous inferences based upon the loss of charac- 
teristic immunofluorescent staining of VWF after stimula- 
tion with PMA,  thrombin, and calcium ionophore A23187 
(Reinders et al.,  1984;  Hormia et al.,  1984;  Sporn et al., 
1986).  Our  results predict either that vascular endothelial 
ceils that lack Weibel-Palade bodies should not be capable 
of regulated  secretion of VWF or that the Weibel-Palade 
body is not the only organelle involved in regulated VWF 
secretion. 
Figure 6.  Quantitative immu- 
noabsorption of mature VWF 
and cleaved proVWF polypep- 
tide  from  purified  [3sS]cys- 
teine-labeled  Weibel-Palade 
bodies. The detergent solubi- 
lized dense organdie was ana- 
lyzed by SDS PAGE  (5 % acryl- 
amide, lane a) and compared 
with supematants obtained by 
prior immunoabsorption with 
monoelonal antibodies to ei- 
ther proVWF (lane b) or ma- 
ture VWF  0ane c).  Immune 
complexes were  removed by 
the addition of a rabbit anti- 
mouse  antiserum  previously 
bound to protein A-Sepharose 
beads. See Materials and Meth- 
otis for details. 
Biochemical analysis of isolated Weibel-Palade bodies in- 
dicate that these organelles contain only two principal poly- 
peptides, identified immunochemically as processed VWF 
(Mr  220,000)  and  the  cleaved  VWF  pro  sequence  (Mr 
100,000) (Figs. 3 and 4). Both polypeptides were localized 
to the Weibel-Palade body by ultrastructural immunocyto- 
chemistry. The apparently stoichiometric quantities of these 
two proteins in the same organelle implies that proteolytic 
cleavage occurs after proVWF (Mr 275,000)  is translocated 
into the storage organelle. An alternative explanation is that 
mature VWF and its cleaved pro sequence remain noncova- 
lently associated and are thus sorted together. However, the 
two proteins clearly separate under the conditions used for 
immunoprecipitation (Fig. 4). A third possibility is that both 
proteins are separately sorted into the same organeUe by a 
process that effectively excludes all other proteins; this ex- 
planation appears far less likely but cannot yet be formally 
ruled out. If cleavage occurs after sorting, then the secretory 
organelle must contain a  specific protease. This prediction 
is under investigation. 
A number of clinical and laboratory observations suggest 
that the adhesive potency of VWF is at least partially related 
to the degree of multimerization (Zimmerman et al.,  1983). 
Sporn et al.  (1986) observed the release of only very large 
multimers from EC stimulated by either the calcium ion- 
phore A23187 or thrombin. The purification of metabolically 
labeled dense organelles permits a direct analysis of VWF 
multimers contained within Weibel-Palade bodies. As shown 
in Fig. 8, the VWF present within this organelle exists as an 
array of high molecular mass multimers that upon reduction 
were seen to consist entirely of Mr 220,000 subunits.  Only 
trace quantities of dimer could be appreciated and very high 
molecular mass species could clearly be discerned. This is 
in marked contrast to the pattern observed in VWF isolated 
from 3-d culture medium by us and others (Lynch et al., 
1986; Sporn et al., 1986). Analysis of the latter material con- 
sistenfly shows a  predominance of dimeric and tetrameric 
Ewenstein et al. Isolation and Composition of Weibel-Palade Bodies  1429 Figure 7. (,4) An endothelial cell in culture labeled with marine monoelonai anti-VWF. All Weibel-Palade bodies identified were labeled. 
A representative Weibel-Palade body is seen in the center of the photograph.  (B) An endothelial cell in culture labeled with a mixture 
of five monoclonal antibodies directed against proVWF sequences. All the Weibel-Palade bodies in all cells were also labeled with this 
PercoU gradient,  and the accumulation of VWF in culture 
species and often fails to demonstrate appreciable quantities 
of larger forms. These differences further support the con- 
cept of separate intracellular pathways for VWF destined for 
storage and regulated release on the one hand and constitu- 
tive secretion on the other. The factors that lead to the high 
degree of multimerization within the storage organelle are, 
at present, unknown. One possibility is that VWF in the stor- 
age granule is composed of protomers that are in some way 
biochemically different than those secreted along the consti- 
tutive pathway. Alternatively, and more likely, intraorganeUe 
conditions such as protein concentration and redox potentials 
predispose to the formation of large multimers (Loscalzo et 
al., 1965). Finally, stimulation by PMA results in the release 
of VWF with a molecular weight distribution identical to that 
seen in isolated dense organelles suggesting that the process 
of regulated secretion per se does not alter the multimeric 
pattern of VWF. 
The physiologic significance of a storage pool of high mo- 
lecular weight VWF remains to be elucidated. It seems rea- 
sonable to  suppose, however,  that locally high concentra- 
tions of thrombin, a known endothelial secretagogue, might 
be transiently  achieved at the site of vascular injury.  This 
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duced releasates of l~SS]cysteine-labeled  endothelial ceils. (A) SDS 
PAGE (4-13% acrylamide) and fluorography of releasates of (a) 
PMA-treated and (b) mock-treated cells and of dense organelles 
from (c) PMA-treated and (d) mock-treated cells. All samples were 
subjected to disulfide reduction with 1% 2-mercaptoethanol (100°C, 
2  min)  before electrophoresis.  Numbers  on left indicate Mr  × 
10  -3.  (B) SDS 2% agarose electrophoresis of the same samples 
under nonreducing conditions (lanes a-d)  compared with VWF 
immunoisolated from 3-d conditioned medium from [JsS]cysteine- 
labeled cells analyzed on a replicate gel. (<) indicates electropho- 
retie mobility of VWF dimer. 
might in turn lead to an amplification of the hemostatic re- 
sponse by the regulated secretion of highly adhesive VWF 
and a consequent increase in platelet binding.  In addition, 
the elaboration of tissue factor on the surface of endothelial 
cells in response to inflammatory mediators such as tumor 
necrosis  factor or  interleukin-1  (Bevilacqua et  al.,  1984, 
1986; Nawroth and Stern, 1986) may lead to increased local 
levels of thrombin.  The  subsequent  increase of regulated 
VWF  secretion may  serve to  amplify the  "procoagulant" 
effects of these agents. 
Most  types  of regulated  secretory cells  contain  within 
them vesicles with electron-opaque, dense cores of highly 
concentrated secretory product surrounded by a unit mem- 
brane (Kelly, 1985). In contrast, the Weibel-Palade body of 
the endothelial cell contains within its "core" a  number of 
lamellar structures embedded within a dense matrix (Burri 
and Weibel,  1968).  Because VWF and its cleaved pro se- 
quence  are  the  major  constituents  of the  Weibel-Palade 
body, it is reasonable to assume that these proteins will make 
a substantial contribution to the unique morphology of these 
organdies. Little is known of the tertiary structure of the pro 
VWF polypeptide. Ohmori et al.  (1982) and Slayter et al. 
(1985)  analyzed  the  structural  characteristics  of purified 
plasma-derived  VWF  by  electron microscopy and  deter- 
mined that the protein takes the form of thin coils consisting 
of end-to-end multimers of a  morphologically identifiable 
protomer. The lamellar fine structure of Weibel-Palade bod- 
ies  may  represent  small  bundles  of highly  polymerized 
filamentous VWF.  The secretion of these large multimers 
appears  to  be  accomplished  by  the  direct  fusion  of the 
Weibel-Palade body with cell plasma membrane in response 
to external stimuli. The distinctive morphology of this secre- 
tory organelle may thus  simply be a  consequence of the 
unique molecular structure of its stored protein. 
The large degree of enrichment of VWF and its cleaved 
pro sequence in the dense organelle peak with respect to 
other intracellular proteins is apparent from the analysis of 
radiolabeled Percoll gradient fractions (Fig.  3).  No other 
cysteine-containing proteins were found to be similarly en- 
riched in these organdies. This is in agreement with work 
of Reinders et al. (1985) which demonstrated that neither im- 
munoreactive thrombospondin nor fibronectin were present 
in isolated organelles from endothelial ceils. As these two 
proteins colocalize with VWF in the a-granules of platelets 
(Holt and Niewiarowski,  1985), their absence in the VWF- 
rich, endothelial organelles suggests different intracellular 
trafficking patterns in the two cell types. In addition to its 
effects on VWF secretion, thrombin stimulates cultured en- 
dothelium to release both tissue-type plasminogen activator 
and platelet-derived growth factor (Levin et al.,  1984; Ross 
et al.,  1986). Both these proteins contain a large percentage 
of cysteine residues and platelet-derived growth factor co- 
localizes with VWF in platelet a-granules, yet neither pro- 
tein was clearly evident in SDS polyacrylamide gel analyses 
of the dense organelle fraction. Thus, either both products 
are stored elsewhere in endothelial cells or are present in 
Weibel-Palade bodies in concentrations below that which 
could be detected by these methods. It is also striking that 
we detect no specific structural proteins associated with the 
secretory organelle using  our labeling  protocol ([35S]cys- 
teine for 3 d in complete medium). Such proteins may be cys- 
teine free or of relatively low abundance. A preliminary ex- 
periment using [35S]methionine-  and cysteine-labeled cells 
also failed to reveal enrichment of any other polypeptides; 
additional  efforts to  identify structural  or other secretory 
constituents of the Weibel-Palade body are in progress. 
Endothelial cells direct newly synthesized VWF along at 
least two different intracellular pathways.  The information 
responsible for such sorting must reside both in the VWF 
protein  itself  and  in  endothelial  subcellular  structures. 
Defects either in the primary structure of VWF or in the 
endothelial cell secretory machinery could lead to defective 
regulated secretion of high molecular weight VWE In fact, 
such a deficiency of highly multimerized VWF,  in plasma 
and/or platelets is observed in patients with type II variants 
of von W'illebrand's  disease. The isolation of VWF storage 
vesicles as reported here, in conjunction with the synthesis 
of appropriate VWF cDNA constructs and the development 
of more highly efficient endothelial cell transfection tech- 
niques,  will permit further delineation of endothelial cell 
sorting signals. 
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